Mural Oncology (MURA) announced the discontinuation of its Phase 3 ARTISTRY-7 trial evaluating nemvaleukin alfa in combination with KEYTRUDA® for platinum-resistant ovarian cancer (PROC). The decision came after interim analysis showed no statistically significant improvement in overall survival compared to chemotherapy.
The combination therapy achieved a median overall survival of 10.1 months versus 9.8 months for chemotherapy (hazard ratio: 0.98). Despite the setback in PROC treatment, nemvaleukin maintained a favorable safety profile across its clinical program, which has treated over 800 patients.
The company will continue its Phase 2 ARTISTRY-6 trial in mucosal melanoma, with topline results expected in Q2 2025. Additional data readouts for less-frequent intravenous dosing in cutaneous melanoma patients are anticipated in Q2 2025 for monotherapy (cohort 3) and H2 2025 for combination therapy (cohort 4).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.